Long-term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis.
Primary biliary cholangitis (PBC) is an auto-immune disease characterized by bile duct destruction that can progress to cirrhosis. A liver biopsy substudy was conducted in the PBC obeticholic acid (OCA) international study of efficacy (POISE) to determine the long-term effects of OCA on liver damage and fibrosis in patients with PBC. POISE is a phase 3, double-blind, placebo-controlled, randomized trial with a 5-year open-label extension that evaluated daily OCA 5 to 10 mg in patients who were intolerant or unresponsive to ursodeoxycholic acid. Liver biopsies were collected from 17 patients at time of enrollment in the double-blind phase and after 3 years of OCA treatment. Histological evaluations were performed by 2 pathologists in a blinded, randomized fashion to determine the effects of OCA on fibrosis and other histological parameters. Collagen morphometry assessments were performed by automated second harmonic generation and 2-photon excitation microscopy to observe quantitative measures of fibrosis. From time of enrollment until 3 years of treatment, most patients had improvements or stabilization in fibrosis (71%), bile duct loss (76%), ductopenia (82%), ductular reaction (82%), interface hepatitis (100%), and lobular hepatitis (94%). Over the 3-year period, we found significant reductions in collagen area ratio (median -2.1; first quartile, -4.6 and third quartile, -0.3 ; P = .013), collagen fiber density (median -0.8; first quartile, -2.5 and third quartile, 0; P = .021), collagen reticulation index (median -0.1; first quartile -0.3 and third quartile, 0; P = .008), and fibrosis composite score (median -1.0; first quartile, -2.5 and third quartile, -0.5; P = .002). A sub-analysis of data from the POISE study demonstrated that long-term OCA treatment in patients with PBC is associated with improvements or stabilization of disease features, including ductular injury, fibrosis, and collagen morphometry features (ClinicalTrials.gov no: NCT01473524 and EudraCT no: 2011-004728-36).